Rigel Pharmaceuticals (RIGL) Corporate presentation summary

Transformational growth strategy

• Focused on expanding the commercial business, advancing the development pipeline, in-licensing, and maintaining financial discipline to drive long-term growth and profitability.

• Progressed from one commercial product in 2020 to three by 2025, with a fourth (VEPPANU) expected in 2026.

• Profitable since Q3 2024, with over $100 million increase in cash through end of 2025.

Commercial portfolio and performance

• Q1 2026 net product sales reached $54.9M, a 26% increase over Q1 2025, driven by TAVALISSE, GAVRETO, and REZLIDHIA.

• TAVALISSE showed 31% sales growth, GAVRETO 7%, and REZLIDHIA 31% year-over-year in Q1 2026.

• TAVALISSE is indicated for chronic immune thrombocytopenia, REZLIDHIA for relapsed/refractory AML with IDH1 mutation, and GAVRETO for RET fusion-positive NSCLC and thyroid cancer.

• Expanded global commercial availability, with TAVALISSE approved in multiple countries and new partnerships for REZLIDHIA.

In-licensing and business development

• Announced exclusive global license for VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC for ER+/HER2-, ESR1-mutated metastatic breast cancer.

• Upfront payment of $70M and $15M in transition payments to Arvinas and Pfizer, with up to $320M in milestones.

• VEPPANU expected to become the largest revenue producer and a key driver of future growth.